- Psyence Group (CSE:PSYG) and iNGENū are collaborating on a palliative care clinical trial in Australia
- iNGENu will jointly design Psyence’s Phase 2b clinical trial using the company’s psilocybin drug candidate in a palliative care environment
- The trial will proceed in accordance with guidelines set by the Therapeutic Goods Administration of the Commonwealth of Australia
- The company’s drug candidate PEX010 is currently being tested in patients with an adjustment disorder related to recent terminal cancer diagnoses
- Shares of Psyence Group (PYSG) are unchanged at C$0.13
Psyence Group (PYSG) and iNGENu are collaborating on a palliative care clinical trial in Australia.
In a press release, the company said that iNGENu will oversee the clinical trial. iNGENu is an Australian-based company with experience working in the psychedelic pharmaceutical drug development market.
The company added that the study will evaluate psilocybin’s use as an assisted psychotherapy versus as just a psychotherapy.
It will use US Food and Drug Administration (FDA)-recommended endpoints to use PEX010 in roughly 75 patients with an adjustment disorder resulting from a recent terminal cancer diagnosis.
Psyence Group said that iNGENu will jointly design the company’s Phase 2b clinical trial using its natural psilocybin drug candidate PEX010 in a palliative care setting.
The trial will be done according to the requirements of the Therapeutic Goods Administration of the Commonwealth of Australia.
PEX010 has previously received authorization from the FDA and Health Canada to enter phase 1 and phase 2 human clinical trials.
Once the study is completed, Psyence will move towards a multinational Phase 2 registrational study.
Shares of Psyence Group (PYSG) are unchanged at C$0.13.
